TUCSON, Ariz.--(BUSINESS WIRE)--Dec. 7, 2005--ProlX Pharmaceuticals announced today that it has been appointed Corporate Partner for a consortium of four leading research institutions that has received a $5.6 million National Cooperative Drug Discovery Group (NCDDG) award from the National Cancer Institute. The research sites include the M.D. Anderson Cancer Center, the Burnham Institute Cancer Research Center, the University of Pittsburgh, and St. Jude Children's Research Hospital. The five-year award will support the discovery and development of targeted therapies designed to treat only the cancer cells and minimize damage to normal, healthy cells.
